|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.300 HKD | -1.67% |
|
-6.36% | -14.24% |
| 11/05 | Global markets live: Alphabet, Cerebras, Compass, GSK, Rockwool… | |
| 11/05 | Hong Kong Stocks Little Changed as U.S.-Iran Talks Remain Deadlocked; LDROBOT Gains on Debut | MT |
| Fiscal Period: December | 2016 | 2017 (CNY) | 2018 (CNY) | 2019 (CNY) | 2020 (CNY) | 2021 (CNY) | 2022 (CNY) | 2023 (CNY) | 2024 (CNY) | 2025 (CNY) |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 5.42 | 5.9 | 5.33 | 5.62 | 5.56 | |||||
Return on Total Capital | 6.74 | 7.2 | 6.6 | 7.02 | 7.11 | |||||
Return On Equity % | 55.25 | 13.22 | 12.12 | 11.82 | 12.53 | |||||
Return on Common Equity | 62.11 | 8.47 | 6.13 | 6.15 | 7.48 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 80.15 | 79.86 | 80.95 | 81.51 | 82.07 | |||||
SG&A Margin | 47.29 | 43.65 | 42.24 | 42.12 | 41.27 | |||||
EBITDA Margin % | 20.44 | 23.45 | 24.35 | 23.88 | 22.79 | |||||
EBITA Margin % | 17.46 | 20.51 | 20.91 | 20.2 | 19.82 | |||||
EBIT Margin % | 17.39 | 20.43 | 20.76 | 20.1 | 19.76 | |||||
Income From Continuing Operations Margin % | 61.85 | 17.38 | 17.61 | 16.57 | 16.69 | |||||
Net Income Margin % | 54.38 | 8.84 | 8.9 | 12.12 | 7.36 | |||||
Net Avail. For Common Margin % | 54.38 | 8.84 | 7.05 | 6.65 | 7.36 | |||||
Normalized Net Income Margin | 36.83 | 4.84 | 2.56 | 5.17 | 7.42 | |||||
Levered Free Cash Flow Margin | -0.65 | 11.45 | 11.47 | 13.53 | 20.74 | |||||
Unlevered Free Cash Flow Margin | 0.07 | 12.4 | 12.66 | 14.17 | 21.28 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.5 | 0.46 | 0.41 | 0.45 | 0.45 | |||||
Fixed Assets Turnover | 3.18 | 3.24 | 2.73 | 2.86 | 3.1 | |||||
Receivables Turnover (Average Receivables) | 7.53 | 6.45 | 5.67 | 6.01 | 5.78 | |||||
Inventory Turnover (Average Inventory) | 2.79 | 2.72 | 2.31 | 2.44 | 2.47 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.53 | 1.29 | 1.05 | 1.26 | 1.37 | |||||
Quick Ratio | 1.39 | 1.15 | 0.9 | 1.11 | 1.23 | |||||
Operating Cash Flow to Current Liabilities | 0.35 | 0.31 | 0.27 | 0.34 | 0.37 | |||||
Days Sales Outstanding (Average Receivables) | 48.47 | 56.62 | 64.36 | 60.92 | 63.18 | |||||
Days Outstanding Inventory (Average Inventory) | 130.67 | 134.35 | 158.08 | 149.75 | 148.03 | |||||
Average Days Payable Outstanding | 126.72 | 108.51 | 126.2 | 90.67 | 101.26 | |||||
Cash Conversion Cycle (Average Days) | 52.42 | 82.47 | 96.25 | 119.99 | 109.96 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 32.48 | 37.21 | 33.32 | 22.7 | 38.18 | |||||
Total Debt / Total Capital | 24.52 | 27.12 | 24.99 | 18.5 | 27.63 | |||||
LT Debt/Equity | 14.66 | 11.22 | 3.6 | 4.86 | 18.18 | |||||
Long-Term Debt / Total Capital | 11.07 | 8.18 | 2.7 | 3.96 | 13.16 | |||||
Total Liabilities / Total Assets | 37.68 | 40.77 | 39.99 | 34.6 | 44.63 | |||||
EBIT / Interest Expense | 15.13 | 13.39 | 10.98 | 19.66 | 22.6 | |||||
EBITDA / Interest Expense | 18.12 | 15.6 | 13.01 | 23.64 | 26.35 | |||||
(EBITDA - Capex) / Interest Expense | 12.57 | 12.77 | 10.85 | 20.39 | 21.9 | |||||
Total Debt / EBITDA | 2.19 | 2.06 | 1.97 | 1.39 | 2.19 | |||||
Net Debt / EBITDA | -0.63 | -0.41 | -0.22 | -0.73 | -0.94 | |||||
Total Debt / (EBITDA - Capex) | 3.16 | 2.52 | 2.37 | 1.61 | 2.64 | |||||
Net Debt / (EBITDA - Capex) | -0.91 | -0.5 | -0.26 | -0.85 | -1.13 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 13.59 | 7.14 | 0.67 | 10.18 | 10.28 | |||||
Gross Profit, 1 Yr. Growth % | 16.6 | 6.76 | -1.53 | 10.94 | 11.04 | |||||
EBITDA, 1 Yr. Growth % | -3 | 23.76 | 1.99 | 8.05 | 5.26 | |||||
EBITA, 1 Yr. Growth % | -3.18 | 26.86 | 1.3 | 6.42 | 8.21 | |||||
EBIT, 1 Yr. Growth % | 13.94 | 26.93 | 0.99 | 6.65 | 8.45 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 282.77 | -69.89 | 2.09 | 3.73 | 11.08 | |||||
Net Income, 1 Yr. Growth % | 427.17 | -82.59 | -8.32 | 50.08 | -33.04 | |||||
Normalized Net Income, 1 Yr. Growth % | 670.8 | -86.14 | -35.59 | 121.22 | 58.21 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 397 | -83.41 | 3.78 | 5.21 | 23.75 | |||||
Accounts Receivable, 1 Yr. Growth % | 44.84 | 8.36 | -1.02 | 9.06 | 19.88 | |||||
Inventory, 1 Yr. Growth % | 3.07 | 20.18 | -14.4 | 19.05 | -4.91 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 1.48 | 8.63 | 7.14 | 3.79 | -0.53 | |||||
Total Assets, 1 Yr. Growth % | 28.24 | 5.82 | -0.72 | 2.84 | 16.21 | |||||
Tangible Book Value, 1 Yr. Growth % | 78.62 | -1.86 | 2.57 | 4.16 | -12.32 | |||||
Common Equity, 1 Yr. Growth % | 80.87 | -1.8 | 2.45 | 4.88 | -4.04 | |||||
Cash From Operations, 1 Yr. Growth % | 0.77 | 16.75 | -3.18 | 9.06 | 40.46 | |||||
Capital Expenditures, 1 Yr. Growth % | 20.35 | -27.47 | -14.12 | -10.09 | 29.02 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -104.73 | -1.77T | 0.51 | 29.89 | 69.05 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -99.5 | -92.76T | 1.73 | 23.33 | 65.68 | |||||
Dividend Per Share, 1 Yr. Growth % | 5.59 | 62.87 | -57.24 | 46.97 | 36.61 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 5.28 | 10.32 | -1.24 | 5.31 | 10.23 | |||||
Gross Profit, 2 Yr. CAGR % | 5.6 | 11.57 | -0.75 | 4.52 | 10.99 | |||||
EBITDA, 2 Yr. CAGR % | -6.46 | 9.19 | 8.15 | 4.98 | 6.65 | |||||
EBITA, 2 Yr. CAGR % | -9.28 | 10.39 | 8.51 | 3.83 | 7.31 | |||||
EBIT, 2 Yr. CAGR % | -2.9 | 19.79 | 8.35 | 3.78 | 7.55 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 86.28 | 7.35 | -47.31 | 2.91 | 7.34 | |||||
Net Income, 2 Yr. CAGR % | 130 | -4.19 | -60.05 | 17.3 | 0.24 | |||||
Normalized Net Income, 2 Yr. CAGR % | 154.21 | 4.18 | -74.18 | 19.73 | 87.1 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 123.39 | -9.2 | -63.11 | 4.5 | 14.11 | |||||
Accounts Receivable, 2 Yr. CAGR % | 24.75 | 26.23 | 3.56 | 3.9 | 14.34 | |||||
Inventory, 2 Yr. CAGR % | 8.09 | 11.3 | 1.43 | 0.95 | 6.4 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 5.62 | 4.99 | 7.89 | 5.46 | 1.61 | |||||
Total Assets, 2 Yr. CAGR % | 27.04 | 16.49 | 2.5 | 1.04 | 9.32 | |||||
Tangible Book Value, 2 Yr. CAGR % | 44.59 | 32.4 | 0.33 | 3.36 | -4.44 | |||||
Common Equity, 2 Yr. CAGR % | 42.35 | 33.28 | 0.3 | 3.65 | 0.32 | |||||
Cash From Operations, 2 Yr. CAGR % | 0.39 | 8.47 | 6.32 | 2.76 | 23.77 | |||||
Capital Expenditures, 2 Yr. CAGR % | 8.75 | -6.57 | -21.07 | -12.12 | 7.71 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -76.38 | -5.25 | 290.9 | 14.26 | 48.19 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -92.3 | -3.99 | 2.83T | 12.01 | 42.95 | |||||
Dividend Per Share, 2 Yr. CAGR % | 16.89 | 31.14 | -16.55 | -21.58 | 42.25 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 8.74 | 5.9 | 3.48 | 2.43 | 6.95 | |||||
Gross Profit, 3 Yr. CAGR % | 8.85 | 5.98 | 4.73 | 3.01 | 6.65 | |||||
EBITDA, 3 Yr. CAGR % | 1.3 | 2.46 | 4.06 | 8.12 | 5.07 | |||||
EBITA, 3 Yr. CAGR % | -0.99 | 1.18 | 4.19 | 7.81 | 5.27 | |||||
EBIT, 3 Yr. CAGR % | 4.26 | 5.89 | 9.89 | 7.78 | 5.32 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 15.68 | 1.47 | 2.05 | -33.96 | 5.56 | |||||
Net Income, 3 Yr. CAGR % | 17.32 | -2.7 | -5.59 | -37.89 | -2.7 | |||||
Normalized Net Income, 3 Yr. CAGR % | 94.15 | -3.1 | -19.47 | -47.06 | 31.4 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 14.52 | -6.1 | -12.22 | -47.68 | 10.56 | |||||
Accounts Receivable, 3 Yr. CAGR % | 13.01 | 19.63 | 16.4 | 5.37 | 8.97 | |||||
Inventory, 3 Yr. CAGR % | 17.02 | 11.98 | 1.97 | 6.99 | -1.04 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 13.63 | 6.62 | 5.71 | 6.5 | 3.42 | |||||
Total Assets, 3 Yr. CAGR % | 6.74 | 19.53 | 10.45 | 2.61 | 5.86 | |||||
Tangible Book Value, 3 Yr. CAGR % | 57.79 | 27.07 | 21.6 | 1.59 | -2.16 | |||||
Common Equity, 3 Yr. CAGR % | 1.22 | 25.78 | 22.09 | 1.8 | 1.02 | |||||
Cash From Operations, 3 Yr. CAGR % | 1.75 | 5.57 | 4.43 | 7.22 | 14.04 | |||||
Capital Expenditures, 3 Yr. CAGR % | 3.41 | -4.99 | -9.16 | -17.57 | -0.12 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -57.14 | 1.92 | -6.43 | 170.75 | 30.2 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -79.68 | 3.11 | -5.03 | 920.21 | 27.62 | |||||
Dividend Per Share, 3 Yr. CAGR % | 11.67 | 30.56 | -9.74 | 0.05 | -5.4 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 14.68 | 14.2 | 4.63 | 3.56 | 6.13 | |||||
Gross Profit, 5 Yr. CAGR % | 14.95 | 14.4 | 4.91 | 4.03 | 7.19 | |||||
EBITDA, 5 Yr. CAGR % | 12.69 | 13.64 | 3.85 | 1.9 | 5.09 | |||||
EBITA, 5 Yr. CAGR % | 11.56 | 12.81 | 2.54 | 0.46 | 5.43 | |||||
EBIT, 5 Yr. CAGR % | 11.51 | 12.79 | 5.71 | 3.21 | 8.95 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 43.52 | 6.49 | -15.54 | -0.01 | 4.13 | |||||
Net Income, 5 Yr. CAGR % | 54.91 | 3.22 | -23.75 | 4.85 | -3.3 | |||||
Normalized Net Income, 5 Yr. CAGR % | 61.38 | 5.27 | -13.09 | -0.51 | 12.96 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 49.47 | -1.36 | -27.21 | -6.5 | -2.51 | |||||
Accounts Receivable, 5 Yr. CAGR % | 16.16 | 17.75 | 9.47 | 13.07 | 15.57 | |||||
Inventory, 5 Yr. CAGR % | 16.7 | 20.44 | 10.52 | 7.43 | 3.72 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 25.95 | 21.57 | 11.3 | 6.15 | 4.05 | |||||
Total Assets, 5 Yr. CAGR % | 26.92 | 25.07 | 5.02 | 11.76 | 9.99 | |||||
Tangible Book Value, 5 Yr. CAGR % | 30.51 | 26.02 | 31.65 | 16.99 | 10.43 | |||||
Common Equity, 5 Yr. CAGR % | 30.82 | 26.43 | 0.85 | 16.41 | 12.86 | |||||
Cash From Operations, 5 Yr. CAGR % | 12.37 | 10.91 | 3.55 | 4.44 | 11.78 | |||||
Capital Expenditures, 5 Yr. CAGR % | 17.08 | 3.28 | -7.18 | -7.91 | -2.75 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -17.05 | 8.85 | 6.4 | 4.65 | 12.46 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -47.63 | 10.11 | 7.59 | 4.67 | 11.84 | |||||
Dividend Per Share, 5 Yr. CAGR % | 23.16 | 30.82 | -0.61 | 6.47 | 7.8 |
- Stock Market
- Equities
- 1177 Stock
- Financials Sino Biopharmaceutical Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















